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Introduction
The aberrant growth of cancer cells can often be explained 
also by a dysregulation of the control of both cell cycle and cell 
division. Cell proliferation encompasses a tightly controlled set of 
events that are regulated by several nuclear protein kinases. These 
include checkpoint kinases (CHK), cyclin-dependent kinases 
(CDK), Polo-like kinases (PLKs), and Aurora kinases (AKs). In 
cancer, these protein kinases are often dysregulated and cause 
uncontrolled cell proliferation and growth.1
In humans, 5 members of the PLK family of serine/threonine 
protein kinases have been identified, and PLK1 is the best char-
acterized.1 PLK1 plays a fundamental role in cell division and 
its inhibition leads to a failure in completing mitosis.2 Moreover, 
PLK1 strongly promotes cell cycle progression.3 As PLK1 is 
overexpressed in a broad range of human tumors, it is currently 
regarded as a potential target for drug development in cancer 
therapy.4 The Aurora kinase (AK) family of serine/threonine 
kinases comprises 3 members referred to as Aurora kinase-A, -B, 
and -C (AK-A, AK-B and AK-C, respectively). AKs are involved 
in centrosome function and mitotic spindle assembly, participate 
in the kinetochore complex, and favor cytokinesis.5 However, 
both AK-A and AK-B have been associated with tumorigenesis 
and their overexpression is frequently observed in multiple tumor 
types, where it is correlated with higher grades of malignancy, 
higher proliferation rates, and poor prognosis.3,6-8 Unlike AK-A 
and AK-B that are ubiquitously expressed in all mammalian 
tissues, AK-C expression is restricted to the testis, where it is 
involved in meiosis.9
As far as malignant blood disorders are concerned, PLK1 
is expressed at high levels in chronic myelogenous leukemia 
(CML),10 acute myelogenous leukemia (AML),11 and acute lym-
phoblastic leukemia (ALL).12 Overexpression of AK-A and -B has 
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polo-like kinases (pLKs) and Aurora kinases (AKs) act as key cell cycle regulators in healthy human cells. In cancer, 
these protein kinases are often overexpressed and dysregulated, thus contributing to uncontrolled cell proliferation and 
growth. t-cell acute lymphoblastic leukemia (t-ALL) is a heterogeneous malignancy arising in the thymus from t-cell 
progenitors. primary chemoresistant and relapsed t-ALL patients have yet a poor outcome, therefore novel therapies, 
targeting signaling pathways important for leukemic cell proliferation, are required. Here, we demonstrate the potential 
therapeutic effects of BI6727, MK-5108, and GSK1070916, three selective inhibitors of pLK1, AK-A, and AK-B/C, respectively, 
in a panel of t-ALL cell lines and primary cells from t-ALL patients. the drugs were both cytostatic and cytotoxic to t-ALL 
cells by inducing G2/M-phase arrest and apoptosis. the drugs retained part of their pro-apoptotic activity in the presence 
of MS-5 bone marrow stromal cells. Moreover, we document for the first time that BI6727 perturbed both the pI3K/Akt/
mtoRC2 and the MeK/eRK/mtoRC1 signaling pathways, and that a combination of BI6727 with specific inhibitors of the 
aforementioned pathways (MK-2206, CCI-779) displayed significantly synergistic cytotoxic effects. taken together, our 
findings indicate that pLK1 and AK inhibitors display the potential for being employed in innovative therapeutic strate-
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also been reported in a number of hematological malignancies, 
which include CML, AML, and ALL.13
Several PLK and AK inhibitors have been synthesized and 
evaluated in vitro and in animal models, and some of them have 
reached phase I/II clinical trials for cancer therapy.14 Regarding 
leukemias, AT9283, an inhibitor of AK-A and -B, has been 
tested in patients with relapsed/refractory AML,15 while baraser-
tib (AZD1152), an inhibitor of AK-B, has been evaluated in a 
phase II clinical trial in AML patients aged ≥60 y.16 Moreover, 
the PLK1 inhibitor BI2536 has been tested in elderly patients 
with refractory/relapsed AML.11
Regarding ALL, preclinical studies on the efficacy of PLK1 
and AK inhibitors have mostly focused on B-cell ALL (B-ALL), 
which is the most common malignancy in children,17-19 while 
very little is known about the relevance of PLK1 and AKs as 
therapeutic targets in T-cell ALL (T-ALL). T-ALL is an aggres-
sive malignant disorder resulting from the occurrence of variable 
mutations in progenitor cells committed to differentiate into 
T-cell lineage. Although the prognosis of T-ALL has improved, 
especially in children, the outcome is still poor for patients refrac-
tory to chemotherapy or for those who relapse.20,21 Therefore, it 
would be very important to identify novel, specific therapeutic 
targets and strategies for improving T-ALL prognosis in patients 
who do not respond to current treatment protocols or relapse.22,23
Here, we analyzed the efficacy of BI6727,24 MK-5108,25 
and GSK1070916,26 3 selective inhibitors of PLK1, AK-A, and 
AK-B/C, respectively, in a panel of T-ALL cell lines and primary 
cells from T-ALL patients. We observed that these drugs were able 
to induce mitotic arrest and apoptosis of leukemic cells. However, 
we demonstrated that BI6727 perturbed both the PI3K/Akt/
mTORC2 and the MEK/ERK/mTORC1 signaling pathways, 
and that a combination of BI6727 with either MK-2206 (an Akt 
inhibitor27) or CCI-779 (temsirolimus, an mTORC1 inhibitor28) 
displayed a significant synergistic cytotoxic effect. Altogether, 
our data demonstrate the potential of PLK1 and AK inhibitors 
in T-ALL treatment.
Results
Inhibitors of PLK1, AK-A, and AK-B affect viability of 
T-ALL cell lines
We first investigated the expression of PLK1, AK-A, and 
AK-B in a panel of T-ALL cell lines. Western blot analysis dem-
onstrated that the CCRF-CEM cell line expressed the lowest lev-
els of both PLK1 and AK-A proteins. BE-13, MOLT-4, Jurkat, 
and HPB-ALL cell lines expressed comparable levels of AK-A. 
PLK1 was expressed at the highest level in Jurkat cells, whereas 
the expression levels of AK-B were similar among T-ALL cell 
lines. PLK1, AK-A, and AK-B were phosphorylated at amino 
acidic residues indicative of their activation (Fig. 1A). The effects 
of the inhibitors on T-ALL cell viability were evaluated by MTT 
assays after 48 h treatment, and the IC
50
 was calculated for each 
drug. Given that PLK1 and AKs regulate cell cycle and mitosis, 
we chose to evaluate drug efficacy at 48 h, which is beyond the 
replication time of all the tested cell lines. Each drug inhibited 
the phosphorylation of the respective target (Fig. 1B). However, 
the AK-A inhibitor MK-5108 also decreased the levels of p-PLK1, 
consistently with AK-A being upstream of PLK1.29
Most cell lines displayed an IC
50
 for BI6727 around 0.02–
0.15 μM, whereas the IC
50
 of CCRF-CEM cells was 1.0 μM 
(Fig. 1C). As to GSK1070916, the IC
50
 ranged from 0.02 to 
11.26 µM, while the IC
50
 for MK-5108 was comprised in a range 
between 0.6 and 2.23 µM. Overall, these findings documented 
that the PLK1 inhibitor, BI6727, was more efficacious than the 
other drugs we tested on this panel of T-ALL cell lines.
Inhibitors of PLK1 and AKs block cells in the G
2
/M phase 
of the cell cycle
In order to better characterize the drug effects on cell cycle 
progression, CCRF-CEM, HPB-ALL, and MOLT-4 cell lines 
were incubated for 48 h with either PLK1 or AK inhibitors at 
their respective IC
50
. Flow cytometric analysis of PI-stained sam-





phase of the cell cycle and a concomitant increase in the G
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/M 





 peak, which was indicative of DNA fragmentation and 
apoptosis. Another interesting consequence of the treatment with 
AK inhibitors was the increase in hyperdiploid cells, as indicated 





) or 4n (G
2
/M), an observation which was consistent with 
the findings previously reported for neuroblastoma cells.24
Moreover, BI6727 treatment of MOLT-4 cell line prevented 
the orderly bipolar mitotic spindle formation, as revealed by 
immunofluorescence staining with an anti-β-tubulin antibody 
(Fig. 2B). In agreement with recent investigations performed in 
solid tumors,30,31 we detected an increase in the expression levels 
of Ser10 p-histone H3 (an established bio-marker for both PLK1 
and AK-A activity) in BE-13 and CCRF-CEM cell lines treated 
with either BI6727 or MK-5108.
Inhibitors of PLK1 and AKs had pro-apoptotic effects on 
T-ALL cell lines and synergized in reducing cell viability
It was then investigated whether the drug effects on cell via-
bility could be also related to apoptosis. 
Flow cytometric analysis of Annexin V/FITC-stained 
MOLT-4 and BE-13 cells demonstrated an increase in both 
early (single-positive for Annexin V) and late (double positive for 
Annexin V and PI) cells in MOLT-4 cells treated with BI6727 
and in BE-13 cells treated with GSK1070916 (Fig. 3A and B). 
We also analyzed caspase-7 and poly (ADP-ribose) polymerase 
(PARP) cleavage. Western blot analysis documented caspase-7 
and PARP cleavage in BE-13, CCRF-CEM, and MOLT-4 cell 
lines treated with BI6727, GSK1070916, or MK-5108 (Fig. 3C). 
Overall, these findings and those highlighted in Figure 2 dem-
onstrated that inhibition of either PLK1 or AK-A/-B activity 
decreased viability of T-ALL cell lines by inducing both a cell 
cycle arrest in the G
2
/M phase of the cell cycle and apoptosis.
PLK1 and AKs directly interact at the molecular level in the 
regulation of cell cycle progression, and more effective antileuke-
mic effects may thus be achieved when targeting of both enzymes 
is combined.32 This could allow the use of lower drug concen-
trations resulting in less severe side effects. We, therefore, inves-
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could synergize in T-ALL cells. HPB-ALL cells were treated 
with increasing concentrations of BI6727 and MK-5108 for 48 
h, either alone or in combination. MTT assays documented the 
existence of a strong synergism (CI < 0.3) at drug concentrations 
lower than their respective IC
50
.
BI6727 also displays pro-apoptotic effects in the presence of 
mouse stromal cells
It is well documented how leukemic cells interact with cells 
of the bone marrow microenvironment that provides a protec-
tion from chemotherapy treatment and induces a drug-resistant 
phenotype.33 MS-5 stromal cells have been reported to secrete a 
variety of growth factors and cytokines as well as extracellular 
matrix proteins34 that could recreate in vitro most of the in vivo 
interactions between leukemic cells and the bone marrow micro-
environment.35 We used a Transwell system that allowed a cross-
talk between MOLT-4 cells and the mouse stromal cells MS-5 by 
the diffusion of small molecules. We analyzed the difference of 
viability of MOLT-4 and MS-5 cells treated with BI6727 when 
grown alone or co-cultured. Cell viability, as assessed by MTT 
assays, decreased (P = 0.0087) when MOLT-4 cells were cultured 
alone if compared with MOLT-4 cells co-cultured with MS-5 
cells (Fig. 4A). However, the drug retained part of its pro-apop-
totic activity, as indicated by PARP cleavage, which was detected 
by western blot (Fig. 4B). Moreover, flow cytometric analysis on 
CD45+-gated cells confirmed that BI6727 retained its pro-apop-
totic effect even when MOLT-4 cells were directly added to MS-5 
monolayers. (Fig. 4C).
PLK1 inhibition influences both PI3K/Akt/mTORC2 and 
MEK/ERK /mTORC1 signaling pathways in T-ALL cells
It is now emerging that PLK1 functions could be intertwined 
with both PI3K/Akt and MEK/ERK signaling.36,37 Therefore, we 
tested whether BI6727 could modulate either of these signaling 
pathways. BI6727 increased the phosphorylation levels of Ser473 
p-Akt (an mTORC2 substrate) as well as those of both Thr389 
p-p70S6K and Ser235/236 p-S6RP, two mTORC1 down-stream 
substrates. In contrast, the total expression levels of these pro-
teins were unaffected by the drug (Fig. 5A). Similar results were 
detected with CCFR-CEM cells (not shown). Therefore, we 
treated MOLT-4 cells with CCI-779 used either as a single agent 
or in combination with BI6727. Although CCI-779 is mainly con-
sidered to be an mTORC1 inhibitor, it is also capable of inhibiting 
mTORC2 activity, especially when used in cells of hematopoietic 
Figure 1. effects of pLK1 and AK-A/-B inhibitors on t-ALL cell viability. (A) Be-13, CCRF-CeM, MoLt-4, Jurkat, and HpB-ALL cell lines were collected, lysed, 
and analyzed by western blot for the expression of pLK1 and AK-A/-B and of their phosphorylated forms. Molecular weights are indicated on the left. (B) 
MoLt-4 cells were treated with BI6727, GSK1070916, and MK-2206 at the respective IC50 for 48 h; next they were collected, lysed, and analyzed by western 
blot. Molecular weights are indicated on the left. CtRL, untreated cells. (C) t-ALL cell lines were treated with the drugs for 48 h. Next the rates of survival 
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lineage.38 Consistently, CCI-779, when used either as single 
agent or in combination with BI6727, blocked the upregulation 
of p-Akt, whereas total levels of expression were unaffected by the 
drugs (Fig. 5A). Overall, these results suggested that inhibition 
of PLK1 may led to upregulated mTORC1/mTORC2 signal-
ing. Nevertheless, it should be considered that mTORC1 activ-
ity could also be regulated through MEK/ERK 
signaling.39 Accordingly, treatment of MOLT-4 
cells with BI6727 resulted in increased phos-
phorylation levels of Thr202/Tyr204 p-ERK and 
of its downstream substrate, Thr573 p-p90RSK 
(Fig. 5B; refs. 40–42). Treatment with the MEK 
inhibitor U0126 blunted the phosphorylation of 
both ERK and p90RSK. Intriguingly, U0126 did 
not affect the basal levels of Ser235/236 p-S6RP; 
however, it completely blocked S6RP phosphory-
lation induced by BI6727. Overall, these findings 
demonstrated that increased S6RP phosphoryla-
tion, which was detected in MOLT-4 in response 
to PLK1 inhibition, was dependent on aberrantly 
activated MEK/ERK signaling.
The relevance of both Akt and mTORC1 
activation induced by BI6727 was investigated 
using MTT assays in MOLT-4 cells treated with 
BI6727 and either MK-2206 (an Akt inhibitor) 
or CCI-779, used as single agents or in combina-
tion. Both of these drugs are now being tested 
in phase I/II clinical trials for patients with leu-
kemias (ClinicalTrials.gov: NCT01369849; 
NCT01403415). Result analysis documented 
that both the drug combinations were synergistic 
(Fig. 5C and D).
Inhibitors of PLK1 and AKs displayed cyto-
toxic effects on T-ALL patient samples
To better assess the effectiveness of PLK1 and 
AK inhibitors as a potential therapeutic agents in 
T-ALL, we examined 6 pediatric T-ALL patient 
samples isolated from bone marrow or periph-
eral blood. Samples expressed variable amount of 
PLK1 and AK-A/-B, as documented by western 
blot analysis (data not shown). The effects of the 
inhibitors on T-ALL lymphoblast samples were 
evaluated first by treating the cells with increas-
ing concentrations of the inhibitors and then ana-
lyzing the rates of viability by MTT assays after 
96 h. A marked reduction in leukemia cell via-
bility was detected. The patient IC
50
 for BI6727 
ranged between 0.11 and 0.48 μM, while for the 
AK inhibitors, it ranged between 0.12 and 1.39 
μM (Fig. 6A). Induction of apoptosis in primary 
T-ALL cells treated with BI6727 (0.5 µM) was 
suggested by flow cytometric analysis of Annexin 
V–FITC/PI-stained samples (Fig. 6B). Moreover, 
western blot analysis of samples treated for 48 h 
with BI6727, GSK1070916, and MK-5108, doc-
umented a significant accumulation of the cas-
pase-7 cleaved form, as well as of cleaved PARP 
(Fig. 6C). Interestingly, and similarly to the 
MOLT-4 cell line, western blotting analysis on 
Figure 2. effects of pLK1 and AK inhibitors on cell cycle progression of t-ALL cell lines. (A) 
CCRF-CeM, HpB-ALL, and MoLt-4 cell lines were treated for 48 h with BI6727, GSK1070916, 
and MK-5108. then, cell cycle analysis was performed by flow cytometry. one representa-
tive of 3 separate experiments is shown, which yielded similar results. the percentages of 
the cells in the various phases of the cell cycle are indicated. (B) MoLt-4 cells were treated 
for 48 h with BI6727 (0.04 µM). then, cells were spun down, fixed, permeabilized, and 
stained with antibody to β-tubulin (green). Nuclei were counterstained with DApI (blue). 
(C) t-ALL cell lines were treated with BI6727, GSK1070916, and MK-5108 at their respective 
IC50s for 48 h, then they were collected, lysed, and analyzed by western blot. Molecular 
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patient samples treated with BI6727 confirmed an increase in 
Ser473 p-Akt, Ser235/236 p-S6RP, and Thr202/Tyr204 p-ERK 
1/2 levels (Fig. 6D).
Discussion
Primary chemoresistant and relapsed T-ALL patients have 
yet a poor outcome; therefore novel therapies, capable of hitting 
signaling pathways critical for T-ALL proliferation, are required. 
Traditional anti-cancer therapies rely on drugs that interfere with 
cell cycle progression. In particular, vinca alkaloids that inter-
act with tubulin, preventing the microtubules polymerization in 
mitotic spindles,43 and taxanes, which bind to tubulin molecules 
and impair the formation of the mitotic spindle,44 block cells in 
the G
2
/M phase of the cell cycle. However, it is well known that 
these compounds cause significant side effects, including neuro-
toxicity.45 Therefore, more specific mitosis-targeting drugs with 
enhanced therapeutic efficacy and fewer side effects should be 
developed. Mitosis-specific kinases, such as members of PLK 
and AK families, were identified as potential targets for cancer 
treatment. Accordingly, several PLK and AK inhibitors have been 
developed over the last years.14 Promising results were obtained 
by targeting PLK1, as its inhibition preferably kills cancer cells 
compared with normal cells.46 The aim of this study was to test 
the therapeutic potential of PLK1 and AK inhibitors (BI6727, 
MK-5108, and GSK1070916) on T-ALL cell lines and primary 
T-ALL lymphoblasts. All these inhibitors are able to interfere 
with cell cycle progression, reducing drastically the cellular pro-
liferation followed by the induction of apoptosis.
Indeed, we have documented that, even if they displayed a 
different efficacy, the PLK1 and AK inhibitors that we tested 
decreased the viability of T-ALL cell lines and primary T-ALL 
lymphoblasts. Among the drugs we tested, BI6727 proved to 
be the most efficacious in terms of IC
50
. Only the CCRF-CEM 
cell line seemed to be less sensitive to BI6727 (IC
50
 = 1 μM). 
Interestingly, western blotting analysis documented that this 
cell line expressed lower levels of PLK1. Overall, our findings 
suggested that PLK and AK inhibitors reduced viability of most 
of the T-ALL cell lines and primary samples we studied, acting 
at submicromolar concentrations. Reduction in cell viability 
was due to both a block in the G
2
/M phase of the cell cycle and 
induction of apoptosis. BI6727 and MK-5108 could be employed 
Figure 3. Inhibition of pLK1 and AK-A/-B induced apoptosis in t-ALL cell lines. (A) MoLt-4 cell line was treated with BI6727 (40 nM) for the indicated 
times, then they were collected and stained with Annexin V-FItC/pI and analyzed by flow-cytometry. (B) Be-13 cells were treated with GSK1070916 (20 
nM) for 48 h, then they were collected, stained with Annexin V-FItC/pI, and analyzed by flow-cytometry. (C) t-ALL cell lines were treated for 48 h with 
BI6727, GSK1070916, and MK-5108 at their respective IC50, then they were collected, lysed, and analyzed by western blot. Molecular weights are indicated 
on the left. CtRL, untreated cells. (D) HpB-ALL cells were treated for 48 h with BI6727 and MK-5108, used either alone or in combination. Cell viability 
was analyzed by Mtt assays. Results are the mean of at least 3 different experiments ± SD. the combination index (CI) value for each data point was 
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together, and the combined treatment resulted in a synergistic 
reduction of cell viability.
Remarkably, BI6727 retained at least part of its pro-apoptotic 
activity also when MOLT-4 cells were co-cultured with MS-5 
stromal cells, which partly mimic the leukemic bone marrow 
microenvironment that is known to promote leukemic cell pro-
liferation and survival.47
An entirely novel finding that emerged from our study is 
that PLK1 inhibition interferes with both PI3K/Akt/mTORC2 
and MEK/ERK/mTORC1, which are 2 signaling pathways fre-
quently hyperactivated in T-ALL.48 Indeed, we documented that 
when MOLT-4 cells were treated with BI6727, Ser473 p-Akt 
levels increased, which is indicative of upregulated mTORC2 
activity. There also was an increase in the phosphorylation levels 
of p-70S6K and p-S6RP, two downstream targets of mTORC1. 
Co-treatment with CCI-779 blunted increased phosphorylation 
of Akt, p70S6K, and S6RP. It should be recalled here that CCI-
779, besides blocking mTORC1 activity, acts as an inhibitor of 
mTORC2, especially when administered for extended periods of 
time (48 h in our case) in cells of hematopoietic lineage.38
Previous studies indicated that MEK/ERK signaling was 
upregulated in PLK1-depleted cells.49 Accordingly, in response 
to BI6727, we detected increased phosphorylation of ERK and 
of its downstream target p90RSK, an activator of mTORC1.50 
Interestingly, treatment with the MEK inhibitor U0126, besides 
reducing ERK and p90RSK phosphorylation levels, prevented the 
BI6727-induced, but not the basal, S6RP phosphorylation. This 
indicated that in cells treated with BI6727, mTORC1 was acti-
vated by the MEK/ERK/ p90RSK axis. Similar findings were also 
observed with T-ALL primary samples.
Both CCI-779 and MK-2206, an Akt inhibitor,27 syner-
gized with BI6727 in reducing the viability of MOLT-4 cells. 
Interestingly, a functional link between PLK1 and mTOR sig-
naling pathway has been recently reported,51 as a combination 
of BI2536 (a PLK1 inhibitor) and PI3K-mTOR dual inhibitors 
eradicated colon cancer stem cells, which overcome conventional 
Figure 4. BI6727 retains pro-apoptotic effects also in the presence of a microenvironment of bone marrow stromal cells. (A) the MS-5 cell line was grown 
in the lower chamber of transwell® 6-well plates, than MoLt-4 cells were added to the upper chamber containing a 0.4-µm-polyester membrane and 
treated with BI6727 (40 nM) for 48 h. the viability of treated cell lines grown alone and co-coltured was then evaluated by Mtt assays. CtRL, untreated 
cells. (B) the MS-5 cell line was grown in the lower chamber of transwell® 6-well plates, then MoLt-4 cells were added to the upper chamber containing 
a 0.4-µm-polyester membrane and treated with BI6727 (40 nM) for 48 h. then, cells were separately collected, lysed, and analyzed by western blot for 
pARp cleavage. Molecular weights are indicated on the left. CtRL, untreated cells. (C) MoLt-4 cells were directly seeded on top of MS-5 cells and treated 
with BI6727 (40 nM). After 48 h, cells were harvested with trypsin/eDtA, washed, and resuspended in binding buffer containing Annexin V-FItC. Cells 
were counterstained with either a pe-conjugated anti-CD45 antibody or with an irrelevant isotypic control antibody and analyzed by flow cytometry 
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cancer therapies and are involved in relapse and in tumor regen-
eration by switching off c-Myc protein.
Therefore, also in T-ALL, the efficacy of PLK1 inhibition 
could be limited by the presence of multiple feedback loops and/
or cross-talk with alternative oncogenic signaling pathways.52
In summary, we characterized the effects of PLK1 and AK 
inhibitors on T-ALL cells, confirming that they are potentially 
useful drugs in the treatment of this disorder. The identification 
of a link between PLK1 and PI3K/Akt/mTORC2 and PLK1 and 
MEK/ERK/mTORC1 signaling pathways supports the use of a 
combined therapy. Hence, our data not only provided insight into 
the effects of PLK1 and AK inhibitors, but may also be important 
in the design of therapeutic protocols that involve targeting of 
both PLK1 and other pathways.
Materials and Methods
Materials
BI6727, GSK1070916, MK-5108, CCI-779, and UO126 
were from Selleck Chemicals. For western blotting and fluores-
cence microscopy, primary antibodies were bought from Cell 
Figure 5. BI6727 upregulates pI3K/Akt/mtoRC2 and MeK/eRK/mtoRC1 signaling in MoLt-4 cells. (A) Cells were treated for 48 h with BI6727 (0.04 µM), 
CCI-779 (0.1 µM), and the combination of the 2 drugs, then they were collected, lysed, and analyzed by western blot. Molecular weights are indicated on 
the left. CtRL, untreated cells. (B) Cells were treated for 48 h with BI6727 (0.04 µM), U0126 (10 µM), or the 2 drugs combined, then they were collected, 
lysed, and analyzed by western blot. Molecular weights are indicated on the left. CtRL, untreated cells. (C) Cells were treated for 48 h with BI6727 and 
CCI-779, used either alone or in combination. the combination index (CI) value for each data point was calculated with the appropriate software for 
dose effect analysis (CalcuSyn). Results are the mean of at least 3 different experiments ± SD. (D) Cells were treated for 48 h with BI6727 and MK-2206, 
used either alone or in combination. the combination index (CI) value for each data point was calculated with the appropriate software for dose effect 























8 Cell Cycle Volume 13 Issue 14























www.landesbioscience.com Cell Cycle 9
Signaling Technology. A FITC-conjugated anti-rabbit IgG anti-
body was purchased from Sigma-Aldrich. Anti-CD45-APC-
conjugated antibody for flow cytometry was obtained from 
Beckton-Dickinson.
Cell culture and primary T-ALL samples
The T-ALL cell lines RPMI-8402, Jurkat, MOLT-4, CCRF-
CEM, BE-13, PF-382, and HPB-ALL were grown in RPMI 
1640, supplemented with either 10% or 20% fetal bovine serum 
(FBS), L-glutamine, and penicillin-streptomycin. Samples from 
T-ALL pediatric patients, obtained after informed consent 
according to the Ethics Committee of Human Experimentation 
guidelines, were isolated using Ficoll-Paque (GE Healthcare Bio-
Sciences AB), and grown as previously described.53 MS-5 mouse 




Diphenyltetrazolium Bromide) assays were performed to assess 
the sensitivity of cells to drugs, as previously described.54,55
Cell cycle and apoptosis analysis
Flow cytometric analysis of the cell cycle was performed using 
a propidium iodide (PI)/RNase A staining according to standard 
procedures, as described previously.56 Samples were analyzed on 
a FC500 flow cytometer (Beckman Coulter) with the appropri-
ate software (CXP, Beckman Coulter). For analysis of apopto-
sis induction, T-ALL cell lines grown alone or co-cultured with 
MS-5 cells were washed twice in PBS, labeled with Annexin V/
FITC in binding buffer, and then analyzed on an FC500 flow 
cytometer after electronic gating on CD45+ leukemic cells.53
Western blot analysis
This was performed by standard methods, as previously 
reported.57 Analysis with an antibody to either β-actin or 
β-tubulin demonstrated equal protein loading.
Fluorescence microscope analysis
Cells were cytocentrifuged to coverslips (200 g, 5 min), fixed, 
and permeabilized with 100% methanol for 3 min on ice. Samples 
were stained with an anti-β-tubulin antibody (1:100), followed 
by FITC-conjugated anti-rabbit IgG (1:500). Slides were then 
treated with ProLong® Gold antifade reagent (Life Technologies 
Italia), containing 4›,6-diamidino-2-phenylindole (DAPI). The 
analysis was performed on an Axio Imager Microscope (Zeiss) 
equipped with an Apotome module. Images were acquired with 
AxioVision software (Zeiss).
Combined drug effect analysis
The combination effect and potential synergy were evalu-
ated from quantitative analysis of dose-effect relationships, as 
described previously.58 For each combination experiment, a com-
bination index (CI) number was calculated using the CalcuSyn 
software (Biosoft). This method of analysis generally defines 
CI values of 0.9 to 1.1 as additive, 0.3 to 0.9 as synergistic, and 
<0.3 as strongly synergistic, whereas values >1.1 are considered 
antagonistic.
T-ALL cell co-culture with MS-5 mouse stromal cells
MOLT-4 cells were seeded at 2.5 ´ 105/ml and, after an over-
night incubation, cell suspension was transferred on the top 
of MS-5 mouse stromal cells (at 70% confluence) and treated 
with BI6727 (40 nM). After 48 h, MOLT-4 cells were collected, 
washed, and incubated with an APC-conjugated anti-CD45 
antibody or with an irrelevant isotypic control antibody. After 
a 30-min incubation, cells were resuspended in binding buffer 
containing Annexin V-FITC and analyzed by flow cytometry 
after electronic gating on CD45+ leukemic cells. In another set 
of experiments, MS-5 cells were grown in the lower chamber of 
Transwell® 6-well plates (Corning) containing a 0.4-µm poly-
ester membrane, then MOLT-4 cells were added to the upper 
chamber and treated with BI6727 (40 nM). After 48 h, the via-
bility of treated cell lines grown either alone or co-cultured was 
evaluated. Furthermore, cells were collected, lysed, and analyzed 
by western blot.
Statistical analysis
The data are presented as mean values from 3 separate experi-
ments ± SD. Data were statistically analyzed by a Dunnet test 
after one-way analysis of variance (ANOVA) at a level of signifi-
cance of P < 0.05 vs. control samples.
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Figure 6 (see previous page). pLK1 and AK-A/-B inhibitors are cytotoxic to t-ALL primary cells. (A) Lymphoblasts from t-ALL patients were cultured in 
RpMI1640 medium supplemented with 20% FBS, insulin-transferrin-sodium selenite, and 10 ng/ml interleukin-7. Mtt assays were performed on samples 
treated for 96 h with BI6727, GSK1070916, and MK-5108. Results are the mean of at least 2 different experiments ± SD. (B) patient samples were treated 
with BI6727 (0.5 µM) for 48 h, then cells were collected, stained with Annexin V-FItC/pI, and analyzed by flow-cytometry for apoptosis. A representative 
sample is shown. CtRL, untreated cells. (C) Western blot analysis of a patient sample treated for 48 h with 0.5 µM BI6727, 0.5 µM GSK1070916, and 0.8 µM 
MK-5108. thirty micrograms (30 μg) of protein/lane were electrophoresed on SDS-pAGe, transferred to nitrocellulose membrane, and probed with the 
appropriate antibodies. one representative of 2 different experiments is shown. Molecular weights are indicated on the left. CtRL, untreated cells. (D) 
Western blot analysis of a patient sample treated for 48 h with 0.5 µM BI6727. thirty micrograms (30 μg) of protein/lane were electrophoresed on SDS-
pAGe, transferred to nitrocellulose membrane, and probed with the appropriate antibodies. one representative of 2 different experiments is shown. 
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